biotech / news / / Livemint
The partners will deploy the highly agile ChAdOx1 viral- vector platform developed by the University of Oxford.
SII will use Oxford’s ChAdOx1 platform to produce Bundibugyo Ebola vaccine doses within 20-30 days.
KEY POINTS
- There are currently no licensed vaccines or therapies for the Bundibugyo Ebola virus.
- WHO has declared the Bundibugyo Ebola outbreak a Public Health Emergency of International Concern.
- India has introduced stringent entry screening, including thermal scans and mandatory forms, for high-risk travelers.
COMPANIES
Summarized by Newsio from Livemint. How we summarize →